Continued Access to Investigational Medicinal Products for Clinical Trial Participants—An Industry Approach
In the conduct of clinical trials for pharmaceutical research, access to investigational medicines following clinical trials is often necessary for the continued health and well-being of the trial participants; it is an ethical obligation under some circumstances, as outlined in the Declaration of H...
| Κύριοι συγγραφείς: | ; ; |
|---|---|
| Τύπος μέσου: | Ηλεκτρονική πηγή Άρθρο |
| Γλώσσα: | Αγγλικά |
| Έλεγχος διαθεσιμότητας: | HBZ Gateway |
| Interlibrary Loan: | Interlibrary Loan for the Fachinformationsdienste (Specialized Information Services in Germany) |
| Έκδοση: |
2019
|
| Στο/Στη: |
Cambridge quarterly of healthcare ethics
Έτος: 2019, Τόμος: 28, Τεύχος: 1, Σελίδες: 124-133 |
| Άλλες λέξεις-κλειδιά: | B
Corporate Responsibility
B post-trial access B low and middle income countries B continued access B research ethics |
| Διαθέσιμο Online: |
Volltext (kostenfrei) Volltext (kostenfrei) |
MARC
| LEADER | 00000naa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1827982098 | ||
| 003 | DE-627 | ||
| 005 | 20221220052655.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221220s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1017/S0963180118000464 |2 doi | |
| 035 | |a (DE-627)1827982098 | ||
| 035 | |a (DE-599)KXP1827982098 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 1 |2 ssgn | ||
| 100 | 1 | |a Kelman, Ariella |e VerfasserIn |4 aut | |
| 245 | 1 | 0 | |a Continued Access to Investigational Medicinal Products for Clinical Trial Participants—An Industry Approach |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a In the conduct of clinical trials for pharmaceutical research, access to investigational medicines following clinical trials is often necessary for the continued health and well-being of the trial participants; it is an ethical obligation under some circumstances, as outlined in the Declaration of Helsinki 2013 Article 34. This obligation becomes particularly important in lower-income countries, where access to medical care may be limited. Although there is agreement among global research and bioethics communities that continued access should be provided with prospectively defined parameters and procedures, the process is complex, as many responsible parties and complicated logistics are involved. Roche Pharmaceuticals developed and publicly posted the company’s policy regarding continued access to investigational medicines in 2013. This article provides insights on the policy, including the parameters that determine when continued access is and is not considered to be appropriate, along with an example from an active clinical development program. It also describes how multiple stakeholders, including those in academia, industry, government, and patient advocacy, have worked together to assess approaches to continued access. Continued access plans should be transparent and agreed to by research participants, investigators, and governments prior to the study and reassessed based on clinical trial evidence of safety and efficacy and availability of adequate treatments, along with relevant international laws and customs. Conducting responsible continued access programs requires close partnerships with investigators, health authorities, and third-party research partners. | ||
| 601 | |a Industrie | ||
| 650 | 4 | |a low and middle income countries | |
| 650 | 4 | |a research ethics | |
| 650 | 4 | |a post-trial access | |
| 650 | 4 | |a Corporate Responsibility | |
| 650 | 4 | |a continued access | |
| 700 | 1 | |a Kang, Anna |e VerfasserIn |4 aut | |
| 700 | 1 | |a Crawford, Brian |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cambridge quarterly of healthcare ethics |d Cambridge : Cambridge Univ. Press, 1992 |g 28(2019), 1, Seite 124-133 |h Online-Ressource |w (DE-627)306655039 |w (DE-600)1499985-7 |w (DE-576)081985010 |x 1469-2147 |7 nnas |
| 773 | 1 | 8 | |g volume:28 |g year:2019 |g number:1 |g pages:124-133 |
| 856 | 4 | 0 | |u https://doi.org/10.1017/S0963180118000464 |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.cambridge.org/core/journals/cambridge-quarterly-of-healthcare-ethics/article/continued-access-to-investigational-medicinal-products-for-clinical-trial-participantsan-industry-approach/5CF1525FF2720D5AE5FCD658484A858F |x Verlag |z kostenfrei |3 Volltext |
| 935 | |a mteo | ||
| 951 | |a AR | ||
| ELC | |a 1 | ||
| ITA | |a 1 |t 1 | ||
| LOK | |0 000 xxxxxcx a22 zn 4500 | ||
| LOK | |0 001 4235387006 | ||
| LOK | |0 003 DE-627 | ||
| LOK | |0 004 1827982098 | ||
| LOK | |0 005 20221220052655 | ||
| LOK | |0 008 221220||||||||||||||||ger||||||| | ||
| LOK | |0 035 |a (DE-Tue135)IxTheo#2022-12-06#B66A20580D85C6EA1E1E52FC8838FA7E60D604A4 | ||
| LOK | |0 040 |a DE-Tue135 |c DE-627 |d DE-Tue135 | ||
| LOK | |0 092 |o n | ||
| LOK | |0 852 |a DE-Tue135 | ||
| LOK | |0 852 1 |9 00 | ||
| LOK | |0 935 |a ixzs |a ixrk |a zota | ||
| OAS | |a 1 | ||
| ORI | |a SA-MARC-ixtheoa001.raw | ||
